LONDON, March 21, 2014 /PRNewswire/ --
On Thursday, March 20, 2014, the
NASDAQ Composite ended at 4,319.29, up 0.27%, the Dow Jones
Industrial Average gained 0.67% to 16,331.05, and the S&P 500
closed at 1,872.01, up 0.60%. The gains were broad based as nine of
ten sectors finished higher. The S&P 500 Health Care Sector
Index finished the day at 686.29, down 0.02%, while the same has
gained 7.91% in the last three months. Investor-Edge has initiated
coverage on the following equities: Dynavax Technologies Corp.
(NASDAQ: DVAX), Forest Laboratories Inc. (NYSE: FRX), Orexigen
Therapeutics Inc. (NASDAQ: OREX) and Endo International PLC
(NASDAQ: ENDP). Free technical research on DVAX, FRX, OREX and ENDP
can be downloaded upon signing up at:
http://www.investor-edge.com/396-register
Shares in Dynavax Technologies Corp. edged 0.53% higher to
finish day at $1.88. A total of 1.40
million shares were traded, which is below the three months average
volume of 4.69 million. The company's shares oscillated between
$1.84 and $1.93 during the session.
Dynavax Technologies Corp.'s shares have advanced 2.17% in the
previous three trading sessions and 3.30% in the last one month,
while the shares have declined 4.08% on YTD basis. The company's
shares are trading above their 50-day and 200-day moving averages
of $1.86 and $1.50, respectively. Moreover, the stock is
trading at a Relative Strength Index (RSI) of 50.56. Sign up today
to read free research on DVAX at:
http://www.investor-edge.com/396-DVAX-.pdf
On Thursday, shares in Forest Laboratories Inc. recorded a
trading volume of 1.74 million shares, as compared with a three
months average volume of 3.61 million shares. The stock ended the
day at $95.69, down 0.32% and at an
intraday range of $95.20 and
$96.77. Shares of the company traded
at a PE ratio of 121.40. Forest Laboratories Inc.'s shares have
gained 0.46% in the previous three trading sessions and 59.40% on
YTD basis, while the shares have fallen by 1.65% in the last one
month. The company's shares are trading above their 50-day and
200-day moving averages of $80.12 and
$54.79, respectively. Furthermore,
the stock is trading at an RSI of 66.07. Sign up today to read free
research on FRX at:
http://www.investor-edge.com/396-FRX-.pdf
Shares in Orexigen Therapeutics Inc. gained 1.21%, closing the
day at $7.53. The stock recorded
trading volume of 1.54 million shares as compared to a three months
average volume of 2.34 million shares. The stock fluctuated between
$7.24 and $7.54 during the trading
session. Orexigen Therapeutics Inc.'s shares have advanced 5.46%
each in the previous three trading sessions and in the last one
month. The company's shares have surged 33.75% on YTD basis. The
company's stock is trading above its 50-day and 200-day moving
averages of $6.82 and $6.34, respectively. Moreover, the stock is
trading at an RSI of 61.39. Sign up today to read free research on
OREX at:
http://www.investor-edge.com/396-OREX-.pdf
Endo International PLC's shares recorded a trading volume of
1.94 million shares, as compared with a three months average volume
of 2.32 million shares. The stock ended the day at $72.90, down 0.29% and recorded an intraday range
of $72.70 and $73.83. Shares of the company traded at a PE
ratio of 56.89. Endo International PLClc's shares have gained 1.60%
in the previous three trading sessions and 8.06% on YTD basis,
while the shares have declined 4.63% in the last one month. The
company's stock is trading above its 50-day and 200-day moving
averages of $71.57 and $53.59, respectively. Furthermore, the stock is
trading at an RSI of 49.38. Sign up today to read free research on
ENDP at:
http://www.investor-edge.com/396-ENDP-.pdf
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and
our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
3. This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
4. If you wish to have your company covered in more detail by
our team, or wish to learn more about our services, please contact
us at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at
compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] http://www.investor-edge.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis.
This document, article or report is prepared and authored by
Investor-edge. An outsourced research services provider represented
by Nidhi Vatsal, CFA, has only reviewed the information provided by
Investor-edge in this article or report according to the Procedures
outlined by Investor-edge. Investor-edge is not entitled to veto or
interfere in the application of such procedures by the outsourced
provider to the articles, documents or reports, as the case may
be.
NOT FINANCIAL ADVICE
Investor-edge makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or
otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-edge is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Investor-edge
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Investor-edge expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Investor-edge does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the
information. The included information is subject to change without
notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
http://www.investor-edge.com/
SOURCE Investor-Edge